Revvity (RVTY): financials, SEC filings and peers

Revvity (RVTY) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in Waltham, Massachusetts.

It was founded in 1937 and joined the S&P 500 on May 31, 1985.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Laboratory Analytical Instruments”.

Revvity at a glance

Revenue (12 months): $2.9B
Revenue growth: +4.1%
Operating margin: 12.3%
Net income (12 months): $238M
Free cash flow (12 months): $558M
Cash: $1.0B
Debt: $3.2B
Diluted EPS (12 months): $2.09

Twelve months to July 5, 2026, from the 10-Q filed August 11, 2026.

Latest twelve months

Over the twelve months to July 5, 2026, Revvity reported revenue of $2.9 billion, about the same as a year earlier (+4.1%).

Its operating margin was 12.3%, down 1.3 percentage points from a year earlier: for every $100 of sales, about $12 was left as operating profit.

Net income was $238 million (8.2% of revenue), 16.7% lower than a year earlier.

Operating cash flow was $628 million and capital spending $70 million, leaving free cash flow of $558 million (19.2% of revenue).

At the end of the period it held $1.0 billion in cash and $3.2 billion in debt, a net debt position of $2.2 billion.

The diluted share count fell 5.0% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $3.8 billion in fiscal 2021 to $2.9 billion in fiscal 2025, a decline of about 5.5% a year.
Operating margin narrowed from 22.9% to 12.5% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2022	2023	2023	2024	2025
Revenue	$3.8B	$3.3B	$2.8B	$2.8B	$2.9B
Revenue growth	1.2%	-13.5%	-16.9%	0.2%	3.7%
Operating margin	32.9%	22.4%	10.9%	12.6%	12.5%
Net income	$943M	$569M	$693M	$270M	$241M
Free cash flow	$1.3B	$594M	$10M	$542M	$509M
Diluted EPS	$8.08	$4.50	$5.55	$2.20	$2.07

Fiscal years as reported in Revvity’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

10-Q filed August 11, 2026 — quarterly report
8-K filed August 4, 2026 — Earnings results; Other event
10-Q filed May 12, 2026 — quarterly report
8-K filed May 5, 2026 — Earnings results; Other event
8-K filed May 1, 2026 — Bylaw or fiscal-year change; Shareholder vote results
10-K filed February 24, 2026 — annual report
8-K filed February 2, 2026 — Earnings results
8-K filed January 13, 2026 — Earnings results; Regulation FD disclosure

All Revvity filings on SEC EDGAR

Companies like Revvity

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Revvity

Is Revvity's revenue growing?

Yes. Revenue for the twelve months to July 5, 2026 was $2.9 billion, up 4.1% from a year earlier, according to its SEC filings.

Is Revvity profitable?

Yes. It earned $238 million in net income over the twelve months to July 5, 2026, a net margin of 8.2%.

Does Revvity have more cash or more debt?

At July 5, 2026 it had $1.0 billion in cash and $3.2 billion in debt, so more debt than cash.

When did Revvity last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on August 11, 2026.

Which companies are similar to Revvity?

In the S&P 500, Revvity is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Dexcom (DXCM) are in the same group.

Understand the numbers

Source: Revvity’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.